MyMD Pharmaceuticals (NASDAQ:MYMD) Stock Price Up 3.2%

MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) shares shot up 3.2% during trading on Monday . The stock traded as high as $2.69 and last traded at $2.58. 64,695 shares changed hands during mid-day trading, a decline of 67% from the average session volume of 194,298 shares. The stock had previously closed at $2.50.

MyMD Pharmaceuticals Stock Up 11.7 %

The company has a market cap of $6.18 million, a P/E ratio of -0.53 and a beta of 2.29. The company has a fifty day moving average of $2.83 and a 200 day moving average of $6.35.

Institutional Trading of MyMD Pharmaceuticals

An institutional investor recently raised its position in MyMD Pharmaceuticals stock. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) by 230.5% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 3,108,473 shares of the company’s stock after purchasing an additional 2,167,871 shares during the period. Mirae Asset Global Investments Co. Ltd. owned 6.11% of MyMD Pharmaceuticals worth $804,000 as of its most recent SEC filing. Institutional investors and hedge funds own 9.64% of the company’s stock.

MyMD Pharmaceuticals Company Profile

MyMD Pharmaceuticals, Inc, a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression.